Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Hexarelin: Evidence Summary
Evidence summary for Hexarelin across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Hexarelin overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Growth hormone secretion | Tier B | 7 | Potent GHS-R1a agonist with consistent GH release in dose-response studies |
| Cardioprotection | Tier C | 2 | Improves cardiac function in GH-deficient patients; direct cardiac receptor binding |